Skip to content

Impact of esketamine on postoperative quality of recovery in outpatient gynecological surgery patients: A randomized controlled trial

Impact of esketamine on postoperative quality of recovery in outpatient gynecological surgery patients: A randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098466
Enrollment
Unknown
Registered
2025-03-10
Start date
2025-03-10
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative quality of recovery

Interventions

Sufentanil group:Anesthesia induction was induced by intravenous injection of sufentanil 0.1 µg/kg combined with propofol 1.5-3 mg/kg. According to the surgical operation and sedation score, propofol
Esketamine group:Anesthesia was induced by esketamine 0.2 mg/kg combined with propofol 1.5-3 mg/kg intravenously. According to the surgical operation and sedation score, propofol 0.5mg/kg was added in

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-65 years old 2. Outpatient gynecological surgery under anesthesia

Exclusion criteria

Exclusion criteria: 1. Refusal to participate in this study 2. Contraindications to ketamine or esketamine, opioids, propofol 3. Alcohol addiction or drug dependence 4. Planning to become pregnant or needing to breastfeed 5. Previous history of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis 6. Severe dementia or speech impairment that prevents them from communicating 7. Moderate or major depressive disorder treated with medication 8. Use ketamine or esketamine within a week 9. Those with a history of transient ischemic attack and stroke in the past 3 months 10. Those with a history of angina, myocardial infarction, heart failure, etc. in the past 3 months 11. Participation in other clinical trials 12. Severe renal impairment (requiring renal replacement therapy); Severe hepatic impairment (Child-Pugh class C)

Design outcomes

Primary

MeasureTime frame
Postoperative quality of recovery at 24 hours;

Secondary

MeasureTime frame
The incidence of high-intensity injection pain;Length of the PACU stay;Sedation success rate;Postoperative quality of recovery at 48 hours;Anxiety and depression scale;Quality of sleep;Postoperative nausea and vomiting;Postoperative pain score;Postoperative fatigue score;Incidence of emergence agitation;Incidence of body movements;Incidence of dizziness or headache and hallucinations or nightmares;Clinician satisfaction;Patient satisfaction;Incidence of intraoperative awareness;

Countries

China

Contacts

Public ContactWang Xulin

First Affiliated Hospital of Zhengzhou University

409327438@qq.com+86 137 0399 8775

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 6, 2026